Tyra’s Dabogratinib and the FGFR3 Switch That Makes Cells Both Stop and Go
Tyra’s Dabogratinib and the FGFR3 Switch that Makes Cells Both Stop and Go
One molecule promises to unlock considerable societal value by solving three different diseases that share a single, strange, signaling protein.
October 28, 2026
Written by:
Jake Simson, PhD
Jake Simson is a Partner at RA Capital Management.
Peter Kolchinsky, PhD
Peter is founder and Managing Partner of RA Capital Management.
Richard Xie, PhD
Richard is a senior health economist at RA Capital Management.
Our team periodically highlights the societal value of medicines and other technologies developed by our portfolio companies. That’s not the same as estimating a drug’s revenues or the value of a company’s stock. Societal value is what it means to the world to have a new medicine come to market. And to understand value in those terms, it’s important to empathize with the patients experiencing the disease that a company is trying to prevent, treat, or cure. These articles therefore provide science and data but also plain English explanations of what it can be like to live with a disease so that anyone can appreciate the magnitude of the problem and the importance of a solution. The intended audience includes health economists, but also doctors and patients and any member of the public, especially if a loved one is suffering from a disease and our article might give them hope for the help that’s on the way.
A strange switch
With the right mutation, roughly one in ten proteins encoded in the human genome could start generating a signal for a cell to grow and potentially become a cancer. But what fibroblast growth factor receptor 3 (FGFR3) does is truly bizarre: this protein makes some cells grow more; in others, it tells them to stop growing. So, an activating mutation, in many cases the same mutation, has opposite effects in different tissues and causes very different diseases.
In the tissue lining the bladder and the upper urinary tract, an activating mutation in FGFR3 is an accelerator stuck to the floor: the cell divides and divides, and a tumor grows. In the cartilage growth plates of a child’s developing skeleton, FGFR3 is a brake that slows bone growth once a child matures. An activating mutation there slams on the brake, permanently, and a child’s bones can barely grow, leaving them very short by the end of puberty, at which time they stop growing altogether.
Same gene. Same activating mutation. Same protein. But the two tissues have wired FGFR3 to do opposite jobs, and so the identical molecular error produces opposite phenotypes: too much growth in one case, too little in the other. And for the first time, a company has created a molecule that exquisitely fits into a pocket of FGFR3 to cleanly turn that switch off, wherever in the body it is stuck – in the bladder, in the upper urinary tract, or in a child’s growth plate.
That molecule is dabogratinib (TYRA-300), an oral, FGFR3-isoform-selective small molecule from Tyra Biosciences (Nasdaq: TYRA), now being evaluated in three separate Phase 2 studies in three diseases. Each has its own story that we’ll explore in more detail below:
- SURF302 is a trial in FGFR3-altered, low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC), where the value proposition for patients (250,000 prevalence, though more relevant is that ~55,000 have been diagnosed with a tumor within the past three years) with a new or recurrent tumor is being able to keep cancer at bay with fewer surgeries and less frequent need to image the bladder through the urethra, allowing a person to live a more normal life.
- SURF303 is a trial in low-grade upper tract urothelial carcinoma (UTUC), where the value proposition for 3,000 newly diagnosed or recurrent patients per year is sparing a kidney rather than removing it.
- BEACH301 is a trial in pediatric achondroplasia, where the goal is restoring normal growth-plate signaling to address the skeletal complications of dwarfism and give the approximately 3,000 kids living with open growth plates and an FGFR3 mutation an opportunity to grow closer to the height and body proportions they would reach if their FGFR3 functioned properly.
Why nobody could hit FGFR3 cleanly before now
FGFR3 belongs to a family of four closely related fibroblast growth factor receptors (FGFR1 through FGFR4) that share highly similar kinase domains. That similarity has been the whole problem. The first FGFR inhibitor to reach patients, erdafitinib (Balversa, sold by Johnson & Johnson), received FDA accelerated approval in 2019 for metastatic urothelial carcinoma with susceptible FGFR2/3 alterations. Erdafitinib is a pan-FGFR inhibitor because it inhibits not only FGFR3 but also FGFR1, FGFR2, and FGFR4. Because it’s not specific for FGFR3, its other activities cause various toxicities that make it hard for adult patients to tolerate the drug for very long: hyperphosphatemia, painful skin and nail changes, dry eye, retinopathy, gastrointestinal disturbances, and stomatitis.
In the trials supporting erdafitinib’s original approval, severe treatment-related adverse events occurred in roughly 41% of patients, with treatment interruptions in about 68% and discontinuations in about 13%.
People whose bladder cancer has a FGFR3 mutation tend to develop a low-grade bladder tumor that will need years of therapy. Because their tumors are not life-threatening, many won’t put up with such serious side effects. And a five-year old with achondroplasia would need treatment for a decade while their bone plates grow and already has safe, effective, injectable options. So an oral pan-FGFR inhibitor would not suit that kid either.
Dabogratinib was designed specifically to inhibit FGFR3 alone. In biochemical assays it inhibits FGFR3 with roughly 14-fold greater activity compared to FGFR2 and more than 20-fold greater activity compared to FGFR1 and FGFR4. Because of this specificity for FGFR3, a doctor should be able to safely prescribe high-enough doses of dabogratinib to fully inhibit FGFR3, the known driver of all three diseases.
So let’s examine each disease closely to appreciate what patients are going through today and what dabogratinib might mean for them if it comes to market.
1. Bladder cancer: “Please keep stuff out of my urethra!”
Bladder cancer is diagnosed in roughly 80,000 Americans a year and about three-quarters of those cases present as non-muscle invasive (NMIBC), which means the tumors are, fortunately, confined to the bladder lining. The alternative to NMIBC is invasive bladder cancer, which means it’s more aggressive and could result in the patient losing their bladder and/or the tumor metastasizing throughout the body, which is much harder to treat and has a high mortality rate.
There are an estimated 700,000 people living with NMIBC in the US as of 2023. NMIBC can be low-grade (slow growing, less scary) or high-grade (more likely to get aggressive and therefore more likely to be treated aggressively). Thankfully, most NMIBCs are low-grade.
Low-grade NMIBCs can be further broken down into low-risk and intermediate-risk. Low-grade, low-risk NMIBC patients already do very well, and it’s hard to help them do much better. We’ll bring them up again later. For now, we’re going to focus on the big population of patients who are living with low-grade NMIBC that have an intermediate-risk of recurrence and an FGFR3 mutation (approximate incidence of 20,000, who live an average of 13 years, for a total prevalence of ~260,000). These are the patients who could benefit from dabogratinib.
People tend not to die from low-grade, intermediate-risk NMIBC. It’s managed and they tend to die of something else. But that doesn’t mean it’s a walk in the park.
Picture the patient journey as the bladder cancer diagnosis plays out today. It often starts when someone notices blood in their urine. That’s usually painless but alarming enough that they’ll call their doctor, who refers the patient to a urologist. In that office, the urologist passes a cystoscope (a tube with a camera) through the urethra into the bladder so the physician can see what’s there. That’s an unpleasant but necessary procedure. This is where I should mention that 75% of bladder cancers occur in men, for whom everything transurethral is especially challenging. For men, their significantly longer urethral length and complex anatomical curves mean that passing instruments through the penis and prostate result in consistently higher documented pain scores. The procedure is unpleasant for women, too. Keep that in mind as you read on.
If the cystoscope shows a tumor in the bladder, the patient returns, typically weeks or even months later, depending on the surgical center availability, for a transurethral resection of bladder tumor (TURBT) under general anesthesia. In this surgical procedure, instruments are fed through the urethra into the bladder to remove the tumor. The tumor is then sent to a pathologist to examine, and the patient goes home and waits, often another week or two, for the pathology results. Low-grade is the better news: it means that, though the tumor will likely come back (and will have to be cut out again), it most likely won’t aggressively grow into the bladder muscle (which makes it hard to cut out and might lead to removal of the bladder) or ever metastasize to the rest of the body (a very bad prognosis).
The toll on patients
On the surface, it might seem reassuring that a cancer won’t kill you as long as you keep cutting it out, but living with NMIBC is a real burden. There’s the emotional toll of knowing you have cancer growing in your body. And any surgical intervention performed under general anesthesia comes with serious risks, particularly for patients with significant comorbidities, as is common in patients with bladder cancer who tend to be older and have other diseases. The recovery from a TURBT can be dehumanizing and brutal; it includes incontinence, agonizingly painful bladder spasms, and the constant threat of blood clots obstructing the urethra, trapping urine and triggering an excruciating, emergency-room-bound crisis. Repeated TURBTs can cause urethral strictures, bladder scarring, and recurrent infections. That’s more pain and more visits to the doctor.
The FDA acknowledged the unmet need to reduce TURBTs by approving Zusduri, an extended-release chemotherapy developed by UroGen and approved as an alternative to TURBT in intermediate-risk NMIBC. The product has launched well, illustrating the doctor/patient demand for such a technology. And yet, as you’ll see, it still leaves a lot to be desired.
A patient with FGFR3-altered low-grade, intermediate-risk disease must battle a chronic, recurring condition that dictates a meaningful share of their calendar for years or even decades. In NMIBC, FGFR3 mutations are associated with a higher risk of recurrence but a lower risk of progression (i.e., less risk of becoming more aggressive). So it’s kind of good news and bad news. Tyra has cited natural history estimates suggesting these FGFR3+ tumors recur in as many as 75% of patients within three years, which – if the underlying data hold up to scrutiny – means the current standard of care is failing most patients most of the time.
When they come to market, oral FGFR3 inhibitors like dabogratinib are going to be much more convenient than these patients’ other options. That’s because, like Zusduri, all the other drugs have to be delivered into the bladder regularly via the urethra. Furthermore, Bacillus Calmette-Guérin (BCG), a weakened, live bacterial strain that is the mainstay of recurrence prevention in the high-risk setting, is generally unavailable in the intermediate-risk setting due to supply shortages.
Tyra has studied the current options and reported that a regimen of intravesical chemotherapy delivered by catheter – an induction of six weekly doses followed by a maintenance of 12 to 24 monthly doses delivered via the urethra – may reduce risk by approximately 44%. But as many as 70% of patients decline this effective treatment, largely due to the treatment burden. Nearly every other therapy in development for these patients including chemotherapy (Zusduri, Relmada’s NDV-01), oncolytic virus (CG Oncology’s cretostimogene, Ferring’s Adstiladrin), and pan-FGFR eluting depot (Johnson & Johnson’s TAR-210) is also delivered into the bladder via a catheter inserted into the urethra.
Furthermore, all these treatments are only offered for a defined period of time and then discontinued. Zusduri is delivered for six weekly bladder instillations. Adstiladrin is delivered quarterly for two years. The oncolytic virus cretostimogene is delivered for an initial induction course of six weekly instillations followed by three instillations at months three and six and a single instillation at months nine and 12 for a total of 14 instillations. For context, each oncolytic virus instillation requires a two-hour dwell time when the patient is instructed to hold the medication in their bladder for an hour or two, repositioning every 15 minutes to ensure all surfaces of the bladder come into contact with the medication, fighting an intense and progressive urgency to urinate the entire time. The pan-FGFR-eluting depot device TAR-210 is deployed for four quarterly device placements.
These limited treatment courses reflect the reality that patients are unlikely to tolerate protracted regimens that require monthly or quarterly trans-urethral intervention. So they help keep the tumor in check for a while, but it tends to recur sometime after preventative therapy is discontinued. And doctors know to watch out for that.
When a patient isn’t being treated to prevent recurrence, they are going through intense monitoring to detect and treat recurrence. The AUA/SUO guideline is specific about the cadence for this exact population: “Intermediate-risk patients with a negative first surveillance cystoscopy should undergo cystoscopy with urine cytology every 3 to 6 months for two years, then every 6 to 12 months for the subsequent two years, and annually thereafter.”
How did they choose these intervals? By calculating how much they could spread out unpleasant cystoscopies without allowing the risk of recurrence before the next visit to get much above 10 – 20%. They are also trying to catch the recurrences while they are small enough that they can be removed during the same procedure, without putting the patient under general anesthesia. Waiting too long results in more complex interventions.
So while a diagnosis of low-grade, intermediate-risk non-muscle-invasive bladder cancer might not sound scary, the constant choice between having one’s urethra violated to deliver a treatment or to screen for recurrence in order to keep the cancer in check can feel like a devil’s bargain.
So far we’ve been talking about low-grade, intermediate-risk NMIBC. Here it’s useful to consider the experience of someone who learns that their low-grade NMIBC tumor is low-risk. After the initial resection of the tumor, they typically do not get treated with anything to prevent recurrence and their monitoring is more sparse: one cystoscopy after three months, one at a year, then repeated annually for five years. After that, if the tumor hasn’t come back, they are considered cured. That’s a lot fewer violations of the patient’s urethra and fewer side-effects from those procedures.
An intermediate-risk patient would love to have their risk downgraded to be lower. Not only do they want to be free of cancer, they want to keep catheters and other medical instruments out of their urethra whenever possible. So we need a well-tolerated solution that is not delivered through the urethra. Oral, subcutaneous, or intravenous will do. The better tolerated the drug, the longer a patient can be on it. The more effective such a drug is, the less frequently a patient should have to undergo cystoscopy for monitoring. That’s pretty much the whole game for the people living with this disease.
Dabogratinib could be that solution. It’s the leading oral FGFR3 treatment in development for NMIBC (the other is Eli Lilly’s selective FGFR3 inhibitor vepugratinib).
We expect that the FDA will decide whether to approve dabogratinib based on the outcome of a randomized, placebo-controlled adjuvant Phase 3 trial. In such a trial, patients take drug or placebo after the initial tumor resection and are followed to see how long it takes for the tumor to come back, which means it can take years to yield data. Tyra’s Phase 2 SURF302 trial in NMIBC was designed as a much more efficient proof-of-concept trial to identify the right dabogratinib dose to carry into that adjuvant Phase 3 trial.
SURF302’s clever shortcut was to dose patients that still had some residual tumor left after surgery. The thinking was that if a dose of dabogratinib can eradicate a residual tumor deliberately left behind after TURBT and hold that response durably, it should be at least as effective at preventing tumor recurrence when given in the adjuvant setting after the tumor has already been fully resected and there is no visible disease left at all. Put simply, a dose good enough to clear a tumor that doctors can still see should be good enough to keep one that they can’t see from coming back.
In SURF302, Tyra enrolled adults with FGFR3-altered, low-grade, intermediate-risk NMIBC and gave them a daily oral dose of dabogratinib. At the August 31, 2026, data cutoff, the trial had dosed 44 patients (22 at 60 mg, 22 at 50 mg), of which 26 patients were evaluable for efficacy. Tyra has since chosen the 60mg dose to take into Phase 3 testing. Among the 14 efficacy-evaluable patients at the 60 mg dose, the objective response rate was 79%, with a 64% complete response (CR) rate. Of the patients with six-month follow-up available, all who had achieved a CR at three months remained in response at six months. Tyra reported that one partial response (PR) at month 3 turned into a CR at month 6, so the tumor response appears to deepen with continued treatment. Safety at 60 mg was, so far, favorable and notably clean of the class-defining pan-FGFR toxicities. The most common treatment-related adverse events seen with dabogratinib were fatigue, intermittent diarrhea, and dry eye, all grade 1 – 2. There were zero treatment-related grade 3 events in patients treated at 60 mg, and there was no clinically significant hyperphosphatemia, nail toxicity, or ocular toxicity at that dose, which are all associated with pan-FGFR inhibition.
These data come from a small, open-label, single-arm study, and the durability of response beyond six months is an open question that will determine whether this early signal holds and will translate to a clinical benefit in the adjuvant setting. But there is reason to be optimistic: multiple data sets testing pan-FGFR inhibitors in NMIBC have demonstrated that so long as pressure is kept on the tumor, complete responses remain durable. This suggests that these tumors were highly dependent on FGFR3 signaling and that the tumor doesn’t mutate enough to develop resistance to the drug. At least not for a while.
Phase 2 data from Johnson & Johnson’s oral pan-FGFR inhibitor erdafitinib draws the clearest before/after picture. In the trial’s intermediate-risk cohort, complete response was durable with no recurrences reported among patients still being treated through a median follow-up of 18 months. But once a patient discontinued erdafitinib, the tumor came back after a median of roughly 10 months, which is about how quickly such a tumor would be expected to come back after TURBT.
Johnson & Johnson’s TAR-210 (an intravesical, erdafitinib-releasing device that is administered every quarter for a year) tells a consistent story from the device side: in the Phase 2 MoonRISe‑2 study, Johnson & Johnson reported an 89% complete response rate with a median duration of response of 18.0 months, but responses are typically achieved at three to six months and treatment itself runs for only about 12 months before the device comes out for good; they observed that tumor comes back nine to 12 months after the device stops delivering drug.
Read together, both the oral and intravesical erdafitinib experiences point to the same conclusion: FGFR3 inhibition (via a pan-FGFR inhibitor) isn’t eradicating the cancer. It’s just putting on the brakes. Take your foot off the brakes and the cancer starts growing again. If only one could inhibit FGFR3 without all the toxicities of a pan-FGFR inhibitor and all the inconvenience of a device that has to be put through the urethra repeatedly so that a patient could safely and tolerably keep the brakes applied to their tumor.
Dabogratinib seems like it should deliver on that promise. The overwhelming majority of patients have shown tumor elimination, shrinkage, or stability during treatment. Tumors that were eliminated haven’t returned. Odds are good that they should stay under control for as long as the patient is being treated. And because the drug is well tolerated, patients should be able to stay on it indefinitely. That’s a lot fewer urethral invasions. Doctors will still want to periodically image the bladder for possible recurrence, but with more data, they might get comfortable stretching out the cystoscopy interval to maybe every 6 – 12 months for two years and then annually thereafter. To get doctors and patients comfortable with less monitoring, one could add periodic urine-based tests that detect FGFR3-mutant tumor DNA shed by the tumor. If that level starts to increase, odds are the tumor is growing and it’s time to do another cystoscopy and resection.
Because TURBT is effective at removing all signs of a primary tumor in most patients, the biggest market opportunity for dabogratinib is preventing post-resection recurrence, when there is no tumor and therefore no need to shrink anything. In that regard, the relevant number from Tyra’s SURF302 trial in partially resected tumors is not the 64% complete response rate or the 79% overall response rate but the number of patients whose tumors shrunk or had stable disease while they were taking dabogratinib. Even stable tumor size demonstrates that the drug is keeping tumor growth in check, which is the point of preventing recurrence. So the Phase 2 data are not inconsistent with the idea that an FGFR3 inhibitor could be very effective, beyond 79%, at suppressing recurrence after resection for as long as a patient is treated. We’ll need the Phase 3 trial to be sure.
Fewer recurrences means patients get fewer procedures. A cynic might wonder if doctors would resent losing income. Community urologists, who see most intermediate-risk NMIBC patients and are reimbursed for the procedures those patients currently need, are often actually incentivized to prescribe a drug, even one that reduces procedure volume. A substantial share of those practices already run in-office dispensing pharmacies, negotiating a spread on oral oncology drugs used, for example, in advanced prostate cancer, such as Xtandi and Orgovyx. The model is described in the literature as a meaningful additional revenue stream that also improves patient continuity of care. Urologists who already dispense oral therapy report that they are glad to do it; it’s better for the patient, good for the practice’s economics, and lighter on the nursing and scheduling burden that intravesical procedures place on staff. So there is already a template for community urology to embrace an oral option rather than resist it.
Of note, in September, Eli Lilly kicked off their own Phase 2 study, FORAY, testing vepugratinib in FGFR3+ intermediate-risk NMIBC (and UTUC, which we discuss below). That the largest pharmaceutical company in the world is chasing Tyra in this indication suggests that they don’t think urologists will hesitate to prescribe an oral drug.
The Pretzel and the Pill: Two tools in one toolbox
It’s easy to assume that dabogratinib would be competing for patients with Johnson and Johnson’s TAR-210, a device implanted quarterly into the bladder that secretes the pan-FGFR inhibitor erdafitinib, thereby inhibiting FGFR3 locally in the bladder without exposing the whole body to all the pan-FGFR-related side-effects. But these products have a lot of complementarity. They aren’t necessarily rivals.
Much as a patient hospitalized with a serious infection is likely treated with a powerful intravenous antibiotic but then discharged on oral maintenance therapy, similarly it might make sense to start off a patient, especially if they have any residual tumor, with TAR-210. It’s a small device, threaded into the bladder and contorted into a pretzel for prolonged indwelling, to sit and release erdafitinib. The drug exposure is impressive and this results in profound efficacy: 89% complete response rate and strong durability while treatment is maintained.
However, if left in too long, the device can start to get crusty, which makes it harder to remove. So it has to be removed after three months. Each procedure is another violation of a patient’s urethra. But a patient might be game to get the powerful, tumor-pounding benefit of TAR-210 for one or two applications and then, when their tumor has been wrestled into submission, they could switch to taking dabogratinib, potentially indefinitely. A one-two punch.
Patients with no residual tumor probably would skip TAR-210 and start with dabogratinib. Straight to the second punch with them.
It’s also possible a higher dose of dabogratinib could do some of TAR-210’s job itself. Tyra is already testing a 70 mg dose alongside the 60 mg dose chosen for Phase 3, and if that higher dose proves potent enough to ablate residual tumor on its own, some patients might not need TAR-210 at all to get started – just a higher dose of the same oral treatment.
Every physician would likely appreciate having the option of using both drugs as needed to manage their patients, giving each a maximal chance of sustained tumor clearance with the fewest possible urethral violations.
Odds are, urologists will test most or all tumors for FGFR3 mutations. But even if they don’t, TAR-210 can also serve as a kind of diagnostic to figure out whether a patient would respond to dabogratinib. If a residual tumor responds to TAR-210, it’s almost certainly driven by an FGFR3 mutation, in which case a patient could likely be switched to dabogratinib later to maintain that response. TAR-210 can even diagnose whether a tumor that recurred while a patient is on dabogratinib (we don’t know how often that might happen, but it’s possible) might respond to a higher dose of dabogratinib.
Here’s how that would work. When a tumor recurs on a drug like dabogratinib, it’s hard to know whether the tumor has learned a new trick that makes its growth independent of FGFR3 signaling (in which case you need to switch to an entirely different drug class, like chemo) or whether the tumor just wasn’t getting enough dabogratinib. Tyra’s own exposure-response analysis suggests a minority of patients, around 20%, may fall short of full target coverage on a standard oral dose. That’s why they are exploring a 70 mg cohort alongside the standard 60 mg dose selected for Phase 3 trials.
To figure out if the tumor is still responsive to FGFR3 inhibition, it would make sense to try TAR-210 in anyone whose tumor has recurred while on dabogratinib. TAR-210 releases so much pan-FGFR inhibitor into the bladder that it would jam the FGFR3 brake down hard. If the tumor shrinks on TAR-210, then it means that FGFR3 is still relevant to that tumor’s growth and the patient potentially could be maintained on a higher dose of dabogratinib. If the tumor doesn’t respond to TAR-210, then it has likely become FGFR3-independent and it’s time to switch to a different drug class.
Together, these two products are useful and complementary tools in a urologist’s toolkit.
Will NMIBC care go generic? Now, yes.
Society saves a ton of money when any disease can be well-managed or cured with a simple medicine that displaces lots of clinic/hospital/doctor time and then eventually goes generic. This is particularly true when the medicine is delivered in a pill. It’s like society has paid off the mortgage on a house and can now live in it rent free. If NMIBC were forever managed with surgery and drugs that have to be instilled into the bladder, with frequent monitoring for recurrence, and all the pain, discomfort, and side effects that accompany those treatments and tests, then we would forever have to spend money on those things. None of those intra-bladder products are easy enough to copy to allow multiple competitors to enter and collapse the price, so the cost of care will only grow, forever.
But a drug like dabogratinib, which is a simple small molecule in a pill, will someday go generic and yet continue to work as well as ever. So if dabogratinib does reduce the need for using more complex ungenericizable therapies and cuts the number of monitoring visits, then it will save society a lot of money over the long run. We’ll model that below.
2. Upper urinary tract carcinoma: “keep your hands off my kidney!”
Upper tract urothelial carcinoma (UTUC), a cancer of the renal pelvis or ureter, is far rarer than bladder cancer. It accounts for only 5 – 10% of all urothelial carcinomas and an estimated 9,300 new cases a year in the US, of which 20% are low-grade, with a prevalence of tens of thousands, some of whom recur each year and contribute to an annual addressable market of 3,000 patients. Even for low-grade, early-stage tumors, the guideline-recommended standard of care is often radical nephroureterectomy – surgical removal of the entire kidney, the ureter, and a cuff of the bladder. UTUC disproportionately affects older adults (peak incidence between ages 70 and 90) who often are already living with age-related decline in kidney function; losing a kidney to cancer would put them at increased risk of ending up with chronic kidney disease. FGFR3 mutations are nearly ubiquitous across low-grade UTUC. You probably see where this is going.
Patients tend to want to hold onto their functioning organs. Clinicians prefer that, too. So both would like a kidney-sparing alternative to the current standard of care of UTUC, and there is already a regulatory template for one: UroGen’s Jelmyto (mitomycin for pyelocalyceal solution), approved by the FDA in 2020 as the first treatment for low-grade UTUC on the strength of a single-arm, 71-patient trial (OLYMPUS) – a 58% complete response rate at three months, with 56% of those responders maintaining it at 12 months. Taken together, Jelmyto showed a 32% complete remission rate at 12 months and the FDA approved it without requiring a controlled trial. So that’s the template Tyra is following with SURF303. But Jelmyto still has to be delivered by ureteral catheter or nephrostomy tube weekly for six weeks, then up to eleven more times, once a month. This is an even more invasive administration route than a bladder catheter, given how much harder the upper urinary tract is to reach than the bladder itself. Because of this treatment burden, our understanding is that most patients forgo the monthly maintenance treatments following the initial treatment induction, and therefore the real-world remission rate at 12 months is almost certainly less than 32%.
Clinically, there is already proof of concept that FGFR3 inhibition can drive responses in this disease. A small Phase 1b study tested a two-month course of the pan-FGFR inhibitor BridgeBio’s infigratinib and reported a 67% response rate, with a 67% median tumor shrinkage among responders with just this short duration of treatment. The problem, like with erdafitinib in NMIBC, was that the drug was just too toxic due to its activity on FGFR1/2/4, and its development in UTUC was terminated.
SURF303 is Tyra’s Phase 2 study testing dabogratinib in FGFR3-altered low-grade UTUC, explicitly framed around a kidney-sparing approach. The goal is to offer patients a well-tolerated, oral drug that could control these tumors well enough that a patient never needs the nephroureterectomy at all. In other words, keep your kidney.
The first patient enrolled has been treated at the 60 mg dose and their disease is in complete remission after three months of treatment. If the biology behind dabogratinib’s efficacy in the bladder generalizes to the genetically similar tumors of the upper tract, the clinical case here is more straightforward than in almost any other cancer indication: take the drug or lose a functioning organ. Tyra has indicated that, in physician conversations, the near-universal preference is to try an oral option before resorting to the instrumentation-heavy alternatives.
3. Achondroplasia: “Let me grow!”
A single point mutation, G380R, in the transmembrane domain of FGFR3 accounts for approximately 99% of achondroplasia. Unlike the bladder, where an activating FGFR3 mutation accelerates cell division, in the cartilage it serves as a brake on bone growth, stopping a child’s bones from growing as long as they normally would before puberty comes to an end.
Achondroplasia occurs in roughly four per 100,000 births in North America (about one in 20,000 to 30,000 births), and there are 140 – 150 newly diagnosed cases a year; the diagnosed prevalent population in the US has been estimated at approximately 14,500 patients. Since you would only treat a child that still has open growth plates, the relevant market size at any one time is about 3,000 children. Short stature is achondroplasia’s most visible feature but far from its most dangerous: foramen magnum stenosis can compress the brainstem and carries an estimated 2 – 5% mortality risk in infancy; obstructive sleep apnea, spinal stenosis, kyphosis, and chronic middle-ear disease are common complications with substantial lifelong impact on patients and their families. Short and disproportionate limbs can also make activities of daily living, like brushing your hair, challenging.
The only approved targeted therapies today are navepegritide (Yuviwel, marketed by Ascendis) and vosoritide (Voxzogo, marketed by BioMarin), C‑type natriuretic peptide (CNP) analogs that work downstream of FGFR3 rather than inhibiting the receptor directly. They require a weekly or daily subcutaneous injection, increase annualized growth velocity by roughly 1.5 to 2.0 centimeters a year versus placebo in trials, and carry US list prices of approximately $430,000 – $500,000 a year. They are important advances in treatment for patients, but because they act on a compensatory pathway rather than the receptor itself, how much they do for the complications that matter most – sleep apnea, spinal and foramen magnum stenosis – is still being actively studied and debated.
Dabogratinib is the only oral, direct, FGFR3-selective small molecule inhibitor in clinical development for achondroplasia, aimed at the receptor mutation itself rather than a downstream workaround. The FDA has granted it both Orphan Drug and Rare Pediatric Disease designations.
BridgeBio tested its pan-FGFR inhibitor infigratinib at a low dose (because of toxicity) and showed the kids grew at a rate that roughly matched the CNP analogs (6 cm/year) but showed no impact on other disease manifestations in the overall population. Tyra has said that in the first quarter of 2027, they will have six months of growth data from 25 children (the same growth-rate endpoint used to evaluate vosoritide) across a range of five doses. Because dabogratinib is selective and better tolerated than a pan-FGFR inhibitor, Tyra expects it will be able to treat kids with high-enough doses that they expect superior growth outcomes and potentially benefits on other measures.
A different set of hereditary FGFR3 mutation leads to a milder growth disorder called hypochondroplasia, with milder physical features and less pronounced skeletal changes than achondroplasia. BioMarin’s CNP analog demonstrated an impressive 2.3 cm/year of additional growth in a hypochondroplasia Phase 3 trial, which suggests that an FGFR3 inhibitor should also work. Hypochondroplasia is the second-most common form of short-limbed dwarfism, with a prevalence of roughly half that of achondroplasia; however, it is believed to be underdiagnosed.
What a working drug might be worth to society
The following is based on a detailed and yet still back-of-envelope, order-of-magnitude exercise meant to estimate the value to society of having a medicine like dabogratinib, based on assumptions of how well it will turn out to work. Our analysis focuses on one of the three indications, NMIBC, which helps us appreciate the scale of the potential societal value across all the indications discussed above.
Note, this is not a valuation of Tyra Biosciences and not a forecast of the company’s revenue.
We use the Generalized Cost-Effectiveness Analysis (GCEA) framework to derive the estimates. GCEA considers a broad range of value elements important to patients, families, and society, including gains in quality of life, reduced healthcare and non-healthcare costs, productivity restored, caregiver burden lifted, and the reassurance that a less invasive option exists for those still under surveillance. It captures the benefits to today’s patients and to future patients who will be diagnosed with NMIBC. By simulating patients’ life trajectories, we estimated the discounted patient-level societal value (i.e., net monetary benefit, assuming zero treatment costs), which then enables us to calculate the aggregate societal value for the patients of today and 70 years of future patients, discounted at 2% per year.
As the analysis sought to understand the societal benefits for patients treated with dabogratinib, the price of the treatment across time does not impact the societal value estimates. But it is worth noting that the future generic price of dabogratinib is likely to be well below the cost of today’s invasive standard-of-care options that have no path to going generic, which is a big driver of the societal savings medicines offer. Consider how much value we continue to get from all the medicines that are now generic and cost barely anything while keeping people productive and out of hospitals. Conventional CEA ignores this but GCEA takes it into account.
We modeled two cases. The Conservative case assumes an 80% complete response rate, durably maintained; the Optimistic case assumes 90%. The labels reflect the range of long-term performance that investors expect rather than what the Phase 2 data have shown so far as response deepens with continued oral dosing.
A reader who disagrees with our assumptions can substitute their own and get a different, potentially equally defensible answer; we have tried to keep the assumptions transparent, and the methods addendum documents each modeling choice and the more conservative alternative to it.
For the roughly 55,000 Americans on therapy at launch – those with persistently recurring FGFR3-altered low-grade intermediate-risk NMIBC, drawn from the ~260,000 living with the disease – plus about 15,000 new patients starting therapy each year thereafter, the value drivers are avoided recurrences and their costs, the quality-of-life burden of resections and surveillance cystoscopies avoided, relief of the fear of recurrence that most surveillance patients carry, reduced monitoring on therapy, caregiver time, and a modest reduction in progression to muscle-invasive disease.
Each treated patient gains roughly $650,000 to $715,000 of discounted lifetime societal value in today’s dollars.
Our GCEA therefore took into account that while society would only be paying for the patients actually taking the drug, many others would get some peace of mind from the upgrade to standard of care. There are 260,000 patients living with potentially recurring FGFR3+ NMIBC at any one time who might benefit from dabogratinib. So even the patients who aren’t being treated (maybe their risk of recurrence is low enough, even if not zero) should derive some peace of mind from knowing that they could go on this simple, well-tolerated oral drug if they needed to be treated again instead of being subjected to today’s standard, more invasive procedures. Moreover, the benefit for patients treated with dabogratinib may extend even beyond recurrence; recall that we flagged tumor size and multifocality as indicators of increased recurrence risk. If dabogratinib treatment results in recurrence of smaller, singular lesions that are easier to excise completely, then future recurrence risk may also be reduced.
A more detailed look at our analysis is here.
Per treated patient (lifetime, discounted at 2%)
| Conservative (CR 80%) | Optimistic (CR 90%) | |
|---|---|---|
| Lifetime discounted societal value per treated patient | $650,153 | $714,574 |
So what we see from our model is that over the 70-year horizon, society enjoys roughly $420 billion to $460 billion of value in today’s dollars (i.e., discounted at a 2% societal discount rate) from NMIBC alone across our two cases, including about $22 billion of peace-of-mind value for those under surveillance; over 100 years, the figure is $480 billion to $525 billion. There is additional value we did not model, as discussed below, as so actual societal value could be meaningfully higher.
Aggregate societal value, discounted to today
| Conservative — 70 yr | Optimistic — 70 yr | Conservative — 100 yr | Optimistic — 100 yr | |
|---|---|---|---|---|
| Treated patients (per-patient value × patient-equivalents) | $399B | $439B | $455B | $500B |
| Peace of mind, monitored population (195,000 × 0.02 × $150K × factor) | $22B | $22B | $26B | $26B |
| Total societal value | $421B | $461B | $480B | $526B |
These estimates are based on 100% penetration for the eligible population and might not reflect real-world launch dynamics. In reality, it takes time to educate physicians and for standards of care to evolve, and meanwhile the patent clock ticks down. So by the time the drug is being used as widely as it’s meant to be used, there may be only a few years left before its price will drop, either due to the pill penalty (i.e., Medicare negotiation nine years after launch) or generic entry if the pill penalty is fixed. So that too results in the US getting a bargain, even though slower market penetration comes at the expense of some patients’ well-being.
What we left out of our model
The GCEA Value Flower. Which petals will demonstrate the value of your medicine?
GCEA can also be represented as a value flower that illustrates the many values a medicine offers to society, and we have modeled only some of the petals. We included a peace-of-mind value for people living with NMIBC under surveillance based on the fear of cancer recurrence for patients living with breast cancer, but we left out the broader “risk reduction” value that all healthy people enjoy from a disease becoming less frightening simply because a new medicine exists. People used to suffer and die from diseases that most people no longer even think about because we have medicines, including vaccines and antibiotics. The peace of mind we get from antibiotics allows us to get scratched up on a hike without worrying that an infected cut might lead to death. Similarly, dabogratinib will make NMIBC, UTUC, and achondroplasia less scary for everyone for the rest of time.
We also skipped scientific spillover, which reflects new uses that may come from dabogratinib in the treatment of other bladder cancer or UTUC patients, those with higher or lower risk than dabogratinib is being developed for, as well as for patients with diseases that we haven’t thought of yet. We only modeled the impacts of dabogratinib in one indication. Maybe dabogratinib can be combined with other medicines in other diseases where FGFR3 is not as central as it is in achondroplasia or NMIBC but still plays a role. Consider how dexamethasone was developed for rheumatoid arthritis decades ago and was discovered during COVID to save lives. While no one could have known that there would be this extra utility to the drug back when it first debuted as a branded medicine, the fact remains that it’s now more valuable than we first realized. Because new uses tend to emerge after a drug has launched and its patent clock has run down, society often ends up spending much less for those other uses compared to the value it gets.
There are other spillovers, such as how doctors and nurses will be freed up from having to do as many TURBTs and cystoscopies and will therefore be able to tend to other patients faster. Consider how the advent of hepatitis C cures reduced the number of people who needed liver transplants, freeing up donor livers to help people with other diseases. Those are spillovers that are hard to model and yet they are real.
What the sales opportunity might look like, if the data hold
We’re going to offer a very rough framework for thinking about potential peak sales without actually claiming that we know what peak sales will be. We’ll acknowledge upfront that the numbers we are transparently plugging into our calculations yield values that are very large, certainly beyond what anyone has had the courage to propose. We aren’t claiming that these numbers will reflect actual peak sales. And yet, at a certain price that is worth it to society and given a certain size of the eligible population size, the math yields some very large estimates.
If Tyra is successful in developing dabogratinib and prices it at $25,000 per month ($300,000 per year), in line with other targeted oncology and rare disease drugs, then we can estimate sales by just multiplying by the number of patients we think will be prescribed the drug.
Let’s do this first as a purely hypothetical, ideal scenario in which all eligible patients are treated. We estimate a treatable market of 55,000 newly diagnosed or persistently recurrent low-grade, intermediate-risk NMIBC patients with an FGFR3 mutation. We start with the 20,000 incident patients and estimate that only roughly 70% have high-enough risk features to warrant treating after the initial TURBT (e.g., large tumors, multifocal); for the other 30%, we only assume treatment for those with two recurrences. So this is roughly a 15,000 incidence of newly diagnosed patients, each treated for an average of three years (some people will turn out to be cured, some will take holidays, some will stay on for longer, but three feels conservative).
In addition, there is a prevalence pool of roughly 50,000 patients at high risk of persistent recurrence who are appropriate candidates to initiate treatment because they had a recent TURBT, or will experience a recurrence and undergo a TURBT in the near future. Over time, the total addressable market will grow from 50,000 to 55,000 as the prevalent pool turns over and an incremental 5,000 patients who are high risk at diagnosis but are lucky enough not to experience a recurrence are treated for a few years before they attempt a drug holiday and discontinue permanently.
In addition to the NMIBC patients, we estimate 3,000 newly diagnosed or recurrent UTUC patients each year, who also might be treated for three years. Taken together, NMIBC and UTUC represent a total prevalent treatable cancer patient population of 64,000 at steady state. We estimate 3,000 achondroplasia patients who still have open growth plates, which adds up to 67,000 total patients who could be on an FGFR3 inhibitor in any given year.
At a price of $300,000, that would represent roughly $20 billion per year in US sales, until the drug goes generic or is price controlled by Medicare Negotiation.
We don’t think that the US will end up spending $20 billion per year on dabogratinib.
Again, sales take time to ramp up and no drug achieves 100% market penetration. And we should assume at least one competitive oral FGFR3 inhibitor (Lilly’s). It’s possible that some NMIBC patients will prefer other drugs, even if they are delivered into the bladder periodically. Some achondroplasia patients may prefer other therapies, even if they are injected. Competition might result in a lower net price than we have modeled. Maybe the class only gets to 70% of patients and Tyra has half that market at $200,000 per year, in which case its peak sales would be closer to $5 billion per year in the US. Allowing five years to reach that peak, total US spend on dabogratinib would be in the range of $30 – 45 billion before it goes generic and the whole class twice that, well below our estimated societal value.
On the other hand, we also didn’t model any sales outside of the US. Most-Favored Nation policy complicates such forecasting, but under typical conditions we would estimate that global sales of a drug or drug class would be about 1.5x greater than the US market, albeit with lower profit margins since ex-US prices would be lower and market penetration in other countries tends to be lower. The rest of the world usually drags its feet when it comes to adopting novel medicines.
These are all rough estimates of value, market sizes, and peak sales meant to show that the innovation Tyra is bringing to market, even at seemingly high prices and high sales forecasts, would represent a bargain to society because of the cost and burden of the diseases their molecule so precisely addresses. We’ll need to see more clinical data to adjust our assumptions; the drug could end up being better or worse than we have modeled. But GCEA shows there is considerable room for error in our estimates before someone should question whether dabogratinib is a bargain in the long run if it works anywhere as well as we have modeled.
Summoning forth more breakthroughs like dabogratinib
As a reference, every $4 billion in sales is just $1 per American per month in premiums. So even a $20 billion per year drug class costs roughly $5 per American per month, until it goes generic. And then it’s pennies. That’s often not pure cost since a medicine can avert the need to spend on healthcare services.
A great example of this is how our spending $20B/year collectively ($5/month) on HIV antivirals keeps over 1M HIV+ Americans healthy. Without antivirals, all those people would develop AIDS and the US would likely need to build and staff over 200 more hospitals to deal with that disease burden, which we estimate would cost about $60B per year ($15/month). Spending $5/month to save $15/month is a bargain even before we consider that these antivirals will go generic within a decade and cost a few nickels per month forever. Although most Americans don’t look at drug prices in this context, the fact that novel medicines sell well in the US signals that Adam Smith’s invisible hand is still able to guide rational market decisions.
Insurance premiums are already high and people have many competing preferences for what to spend their money on. But given the right information, we think many people could spot the bargain dabogratinib offers to them personally. Just consider our description of what it’s like to have NMIBC, UTUC, or achondroplasia with and without the existence of dabogratinib. Now consider that everyone in America has a roughly 1% chance of needing an FGFR3 inhibitor at some point in their life, higher for men, lower for women. If each person has even nine people close to them (parents, siblings, spouse, children), then collectively that’s a one in 10 chance that they or someone close to them will need an FGFR3 inhibitor.
Would you rather know such a drug exists or are you okay if it doesn’t? Just contemplating what it’s like to manage NMIBC with constant violations of one’s urethra, we think most people would say they would wish for such a drug to exist to spare them the pain and discomfort.
So now would you pay a few dollars a month for 13 years to get your wish?
And before you answer, know that the money you’re already spending on different drugs, such as Keytruda, Ibrance, and Xtandi, will be freed up around the time dabogratinib could be approved, because those drugs are going generic/biosimilar.
If you would be willing, then say no more, because that’s exactly how the US insurance system summons forth innovation like dabogratinib.
We can look forward to the launch of dabogratinib because innovators and investors have a credible expectation that society will value it and pay for it. That expectation is credible because insurance plans cover many other targeted therapies for cancers and orphan diseases that are similarly burdensome to NMIBC, UTUC, and achondroplasia. So by our willingness to spend on the drugs that are on the market today, the US has summoned forth dabogratinib. And once it comes to market, assuming that insurance plans value it enough, Tyra’s financial success will validate and affirm everyone’s confidence in America’s willingness to reward progress, and they will continue to invest in the development of more such medicines for the many other unmet needs that still need our attention. Rewarding success begets more investment to generate yet more success.
RA Capital Management is an investor in Tyra Biosciences. This article is for informational purposes only and does not constitute investment advice. Please see Disclosure for additional important information.